In the present study, 11 of 44 patients (25%) with intestinal or mixed-type gastric cancers were HER2-positive, while just 1 of 69 patients (1.4%) in diffuse or indeterminate-type gastric cancers were HER2-positive. The gene discussed is ERBB2; the disease is gastric cancer.